Methods and compositions for CNS delivery of heparan N-sulfatase
The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.
1. A stable formulation for intrathecal administration comprising a heparan N-sulfatase (HNS) protein at a concentration of at least 10 mg/ml, a polysorbate surfactant, and phosphate at a concentration of no greater than 10 mM.
2. The stable formulation of claim 1 , wherein the HNS protein is present at a concentration ranging from approximately 10-20 mg/ml.
3. The stable formulation of claim 1 , wherein the HNS protein comprises an amino acid sequence of SEQ ID NO:1.
4. The stable formulation of claim 1 , wherein the formulation comprises NaCl.
5. The stable formulation of claim 4 , wherein the formulation comprises NaCl at a concentration of approximately 145 mM.
6. The stable formulation of claim 1 , wherein the polysorbate surfactant is polysorbate 20.
7. The stable formulation of claim 6 , wherein the polysorbate 20 is present at a concentration of approximately 0.02%.
8. The stable formulation of claim 1 , wherein the phosphate is present at a concentration of approximately 5 mM.
9. The stable formulation of claim 1 , wherein the formulation has a pH of approximately 5.0-8.0.
10. The stable formulation of claim 9 , wherein the formulation has a pH of approximately 7.0.
11. The stable formulation of claim 1 , wherein the formulation further comprises a stabilizing agent.
12. The stable formulation of claim 11 , wherein the stabilizing agent is sucrose.
13. The stable formulation of claim 12 , wherein the sucrose is present at a concentration ranging from approximately 0.5-2.0%.
14. The stable formulation of claim 1 , wherein the formulation is a liquid formulation comprising 175 mM NaCl or 2% sucrose.
15. The stable formulation of claim 1 , wherein the formulation is formulated as lyophilized dry powder.
16. A stable formulation for intrathecal administration comprising a heparan N-sulfatase (HNS) protein at a concentration of approximately 15 mg/ml, NaCl at a concentration of approximately 100-200 mM, polysorbate 20 at a concentration of approximately 0.02%, phosphate at a concentration of approximately 5 mM, and a pH of approximately 7.0.
17. The stable formulation of claim 16 , wherein the NaCl is at a concentration of approximately 145 mM.
18. The stable formulation of claim 16 comprising a heparan N-sulfatase (HNS) protein at a concentration up to approximately 15 mg/ml, NaCl at a concentration of approximately 145 mM, polysorbate 20 at a concentration of approximately 0.02%, phosphate at a concentration of approximately 5 mM, sucrose at a concentration of approximately 0.5-2%, and a pH of approximately 7.0.
19. A stable formulation for intrathecal administration comprising a heparan N-sulfatase (HNS) protein at a concentration up to approximately 15 mg/ml, NaCl at a concentration of approximately 145 mM, polysorbate 20 at a concentration of approximately 0.02%, phosphate at a concentration of approximately 5 mM, glucose at a concentration of approximately 0.5-10%, and a pH of approximately 7.0.